ENABLE MRI (Magnetic Resonance Imaging)

NCT ID: NCT02652481

Last Updated: 2021-01-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2018-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to collect data to confirm the safety and effectiveness of the Image Ready™ MR (Magnetic Resonance) Conditional Defibrillation System when used in the 1.5T (Tesla) MRI environment under the labeled Conditions of Use (Phase I).

Additionally, the study will assess medically necessary MR scans according to the labeled Conditions of Use to provide real-world scanning data (Phase I and Phase II).The study also aims to demonstrate the continued ability of the ImageReady MR Conditional Defibrillation System to sense and detect ventricular fibrillation (VF) post MRI scan by collecting and analyzing data from spontaneous VF episodes, "for-cause" VF inductions, and from an optional VF induction Sub-study.

.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Magnetic Resonance Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ImageReady MR Conditional Defibrillation System Group

Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).

De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit

Group Type OTHER

ImageReady MR Conditional Defibrillation System

Intervention Type DEVICE

ImageReady MR Conditional Defibrillation System Components:

Device Name Device Model Number Pulse Generators Phase I and II Phase II Only \* CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD\* AUTOGEN EL ICD\* AUTOGEN X4 CRT-D\* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI\* Suture Sleeve for INGEVITY MRI\* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)\* Suture Sleeve for RELIANCE 4-FRONT leads\*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads

\* May only be used internationally outside the US

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ImageReady MR Conditional Defibrillation System

ImageReady MR Conditional Defibrillation System Components:

Device Name Device Model Number Pulse Generators Phase I and II Phase II Only \* CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD\* AUTOGEN EL ICD\* AUTOGEN X4 CRT-D\* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI\* Suture Sleeve for INGEVITY MRI\* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)\* Suture Sleeve for RELIANCE 4-FRONT leads\*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads

\* May only be used internationally outside the US

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Phase I: Subject is indicated per guidelines and will receive a CRT-D or ICD system OR Subject is implanted with a functional and stable CRT-D or ICD system Phase II: Subject is implanted with a functional and stable CRT-D or ICD system
2. Subject will receive or is implanted with an ICD or CRT-D pulse generator in the left or right pectoral region
3. Subject is able and willing to undergo an MR scan without intravenous sedation (Phase I only)
4. Subject is willing and capable of providing informed consent and participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol
5. Subject is age 18 or above, or of legal age to give informed consent specific to state and national law


1. Unstable heart failure requiring hospitalization in the last 30 calendar days
2. Unable to tolerate sedation (e.g. IV (intravenous sedation )sedation, general anesthesia)
3. Planned cardiac revascularization procedure
4. Right Ventricular Lead R wave is less than 5 mV(milliVolt)

Exclusion Criteria

1. Subject implanted with an ICD or CRT-D pulse generator with battery at Explant status
2. Subject has other active or abandoned implanted cardiac rhythm devices, components or accessories present such as pulse generators, leads, lead adaptors or extenders
3. Presence of metallic objects that represent a contraindication to MR imaging at the discretion of the Radiologist and impacting the ability to conduct the study protocol
4. Subject needs or will need a medically necessary MR scan, before completing the 1-month post-MR follow-up visit (Phase I only)
5. Subject with:

* A history of syncope related to brady-arrhythmia
* A history of syncope of unknown etiology
* Sinus pauses (Pause \> 2 s)
* Permanent or intermittent complete AV (Atrioventricular ) block
* Documentation of progressive AV nodal block over time
* Trifascicular block (alternating bundle branch block or PR \> 200 ms (interval between P wave and R-wave) with LBBB ( Left bundle branch block) or other bifascicular block) Note: It is required to run a 12 lead ECG (Electrocardiography) and a 10s rhythm strip to document this exclusion criterion. During ECG acquisition, subjects must be in either their own intrinsic rhythm or, in subjects with an existing device implant, the device must be programmed to VVI (ventricular demand pacing) 40 ppm.
6. Subject is not clinically capable of tolerating the absence of pacing or Resynchronization therapy support in a supine position for the duration that the pulse generator is in MRI Protection Mode, per Physician discretion
7. Subject is not clinically capable of tolerating the absence of Tachycardia therapy support for the duration that the pulse generator is in MRI Protection Mode, per Physician discretion
8. Subjects with a planned RA( right atrium), RV ( right ventricle) or LV (left ventricle) lead revision or extraction within 30 days of enrollment (Phase I only)
9. Subjects with an implanted lead that is planned to be extracted during the study implant procedure
10. Subjects currently requiring dialysis
11. Subject has a mechanical heart valve
12. Subject has a known or suspected sensitivity to dexamethasone acetate (DXA)
13. Subject is currently on the active heart transplant list
14. Subject has documented life expectancy of less than 12 months
15. Subject is enrolled in a concurrent study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific
16. Women of childbearing potential who are or might be pregnant, and will receive an ICD or CRT-D pulse generator
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gregory Voss

Role: STUDY_DIRECTOR

Boston Scientific Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Center Research, LLC

Huntsville, Alabama, United States

Site Status

Cardiology Associates of Northeast Arkansas

Jonesboro, Arkansas, United States

Site Status

Huntington Memorial Hospital

Pasadena, California, United States

Site Status

University of California - San Diego-N

San Diego, California, United States

Site Status

John Muir Medical Center

Walnut Creek, California, United States

Site Status

Manatee Memorial Hospital

Bradenton, Florida, United States

Site Status

Lakeland Regional Medical Center

Lakeland, Florida, United States

Site Status

University Community Hospital

Tampa, Florida, United States

Site Status

Emory University Hospital

Atlanta, Georgia, United States

Site Status

St. John's hospital

Springfield, Illinois, United States

Site Status

St. Vincent's Hospital

Indianapolis, Indiana, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

Marquette General Hospital

Marquette, Michigan, United States

Site Status

Centracare Heart and Vascular Center

Saint Cloud, Minnesota, United States

Site Status

HealthEast St. Joseph's Hospital

Saint Paul, Minnesota, United States

Site Status

North Mississippi Medical Center

Tupelo, Mississippi, United States

Site Status

Cox Health

Springfield, Missouri, United States

Site Status

Northwell Health

New York, New York, United States

Site Status

University of North Carolina Hospital

Chapel Hill, North Carolina, United States

Site Status

OhioHealth Research and Innovation Institute - Riverside Methodist Hospital

Columbus, Ohio, United States

Site Status

The Toledo Hospital

Toledo, Ohio, United States

Site Status

Providence St. Vincent Medical Center

Portland, Oregon, United States

Site Status

Bryn Mawr Medical Specialists

Bryn Mawr, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Rapid City Regional Hospital

Rapid City, South Dakota, United States

Site Status

St. Thomas Research Institute, LLC

Nashville, Tennessee, United States

Site Status

SouthEast Texas Clinical Research Center

Beaumont, Texas, United States

Site Status

University of Texas Houston Health Science Center

The Woodlands, Texas, United States

Site Status

Trinity Mother Frances Health System

Tyler, Texas, United States

Site Status

University of Utah Hospital and Clinics

Salt Lake City, Utah, United States

Site Status

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

Virginia Commonwealth University Health System

Richmond, Virginia, United States

Site Status

Providence Regional Medical Center Everett

Everett, Washington, United States

Site Status

PeaceHealth Southwest Medical

Vancouver, Washington, United States

Site Status

Academisch Ziekenhuis Middelheim

Antwerp, , Belgium

Site Status

Deutsches Herzzentrum Berlin

Berlin, , Germany

Site Status

Medizinische Hochschule Hannover MHH

Hanover, , Germany

Site Status

Klinikum Magdeburg

Magdeburg, , Germany

Site Status

Prince of Wales Hospital

Hong Kong, , Hong Kong

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Soroka MC

Petah Tikva, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Hadassah Hebrew University Medical Center

Tel Litwinsky, , Israel

Site Status

Fondazione di Ricerca e Cura 'Giovanni Paolo II'

Campobasso, , Italy

Site Status

Azienda Ospedaliera Universitaria Federico II

Napoli, , Italy

Site Status

Azienda Ospedaliera San Camillo-Forlanini

Roma, , Italy

Site Status

Ospedale S.G. Calibita Fatebenefratelli - Isola Tiberina

Roma, , Italy

Site Status

Ospedale san giovanni calibita

Roma, , Italy

Site Status

Policlinico Casilino

Roma, , Italy

Site Status

Osp. S. Maria Della Misericordia

Udine, , Italy

Site Status

Institut Jantung Negara

Kuala Lumpur, , Malaysia

Site Status

University of Malaya Medical Centre

Kuala Lumpur, , Malaysia

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Heart and Chest Hospital

Liverpool, , United Kingdom

Site Status

Guys and St. Thomas NHS Foundation Trust

London, , United Kingdom

Site Status

Freeman Hospital

Newcastle, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Germany Hong Kong Israel Italy Malaysia Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Rinaldi CA, Vitoff PJ, Nair DG, Bernstein R, Mountantonakis SE, Rapacciuolo A, Carter N, Tse HF, Green UB. Safety of magnetic resonance imaging scanning in patients with cardiac resynchronization therapy-defibrillators incorporating quadripolar left ventricular leads. Heart Rhythm. 2020 Dec;17(12):2064-2071. doi: 10.1016/j.hrthm.2020.08.020. Epub 2020 Sep 7.

Reference Type DERIVED
PMID: 32911050 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C1734

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Radiation-Free Heart Catheterization Using MRI
NCT02739087 ACTIVE_NOT_RECRUITING NA